Biosimilars Market To Reach USD 44.56 Bn by 2026 Growing at a CAGR of 30.8%


Reports And Data has published a report on the Global Biosimilars Market.  It includes a database of all market essentials, with key facts and figures represented in the form of tables, pie charts, graphs, etc., giving the reader a better understanding of the market. Currently, the Biosimilars market is witnessing industry-wide development. The research study presents a detailed analysis of the industry and projects the future market growth by examining the current growth factors, opinions of industry experts, and other industry-related information derived from reliable sources. The report offers estimates for Global Biosimilars Market Forecast till 2026.

Biosimilars Market Size – USD 5.10 Billion in 2018, CAGR of 30.8%, Biosimilars Industry Trends – Product launches and research for advanced Biosimilars

According to the current analysis of Reports and Data, the global Biosimilars market was valued at USD 5.10 Billion in 2018 and is expected to reach USD 44.56 Billion by year 2026, at a CAGR of 30.8%. Biosimilar are alternatives to existing patented, and approved biologicss and possess similar medicinal properties as compared to the original biologics. The biosimilars vary a little from original biologics in terms of structure but must have similar safety and efficacy as compared to the originator biologics. Biosimilars development does not require Phase II clinical trial for approval and the focus is put on determination of ‘biosimilarity’ to the reference originator biologics. Thus it has much reduced clinical development timelines and reduced product costs as compared to use of original biologics.

Click here to get a sample of the Global Biosimilars Market Research Report: @

Most exhaustive List of Top key vendors in Biosimilars Market are:

Amgen, Biocon, Celltrion, Dr. Reddy’s Laboratories, Mylan, Pfizer, Samsung Biologics, Sandoz, Stada Arzneimittel, and Teva Pahrmaceutical .

Scope of the Report:

The all-encompassing research weighs up on various aspects including but not limited to important industry definition, product applications, and product types. The pro-active approach towards analysis of investment feasibility, significant return on investment, supply chain management, import and export status, consumption volume and end-use offers more value to the overall statistics on the Biosimilars market. All factors that help business owners identify the next leg for growth are presented through self-explanatory resources such as charts, tables, and graphic images.

Reports and Data has segmented the Biosimilars market:

Type (Revenue, USD Million; 2016–2026)

  • Recombinant Non-glycosylated Proteins
    • Insulin
    • Recombinant Human Growth Hormone
    • Granulocyte Colony-stimulating Factor
      • Filgrastim
      • Pegfilgrastim
    • Interferons
      • Interferon-Beta
      • Interferon-Alpha
    • Recombinant Glycosylated Proteins
      • Erythropoietin
      • Monoclonal Antibodies
        • Adalimumab
        • Bevacizumab
        • Infliximab
        • Rituximab
        • Trastuzumab
        • Other Monoclonal Antibodies
      • Follitropin
      • Etanercept
    • Recombinant Peptides
      • Glucagon
      • Calcitonin

Disease Type (Revenue, USD Million; 2016–2026)

  • Oncology
  • Blood Disorders
  • Chronic Diseases
  • Autoimmune Diseases
  • Growth Hormone Deficiency
  • Infectious Diseases
  • Other Diseases

Regional Outlook (Revenue, USD Million, 2016 – 2026)

    • North America
      • U.S.
      • Canada
    • Europe
      • Germany
      • France
      • U.K.
      • Spain
      • Italy
      • Rest of the Europe
    • Asia Pacific
      • China
      • Japan
      • India
      • Southeast Asia
    • Latin America
      • Brazil
    • Middle East & Africa

Get Your Copy at Discounted Price@

The global market is driven by various of factors such as global prevalence of target disease prevalence across the globe, launch of biosimilars by various market players, favorable investments scenario, and upcoming patent expiry.

The Biosimilars market is characterized by presence of significant number of pharmaceutical giants as well as emerging players operating across the globe. Additionally, availability of research fundings, demand for cheaper biologics alternative and favorable regulatory scenario in Europe and Asia pacific is propelling the market in these regions. However, some regions such as U.S are facing slow adoption of biosimilars with first biosimilar approved in 2015 for Sandoz’s Zarxio (filgrastim), and 3, 5, and 7, biosimilars approved by FDA in 2016, 2017, and 2018, respectively..

Further key findings from the report suggest:

  1. Biosimilars market is growing at a CAGR of 2% in Asia Pacific followed by North America and Europe, with 21.0% and 31.4% CAGR, respectively. High chronic disease prevalence across the globe is the key factor to accelerate the market growth during forecast period across all regions.
  2. As of 2018, Recombinant Non-glycosylated Proteins is the dominating Biosimilars which holds over 60% of the global market. European regional market is the chief revenue generating source for this product segment, followed by North America and Asia-Pacific regions.
  3. Recombinant Glycosylated Proteins is expected to be the fastest growing market segment during forecast period 2019-2026 with a CAGR of 33.4%. However, regulatory obstacles and manufacturing complexity are major challenge for the market growth of this market segment.
  4. Recombinant Peptides segment was estimated to account for USD 501.00 million in 2018 and is expected to grow reach USD 4.38 Billion by year 2026.
  5. Asia Pacific is expected to account for the 32.8% of the global Biosimilars market. Developing nations such China, and India are likely to witness high growth.
  6. Some regions such as U.S. and Latin America are facing slow adoption of biosimilars due to stringent regulatory framework..

For further information on this analysis, please visit @

The research provides answers to the following key questions:

  1. What will be the market size and growth rate of the Biosimilars market for the forecast period 2019 -2026 across different regions?
  2. What are the key driving forces expected to shape the future of the industry worldwide?
  3. What strategies are the prominent vendors adapting to stay ahead of their competitors?
  4. Which major trends are impacting the development of the Biosimilars market worldwide?
  5. Which factors can hinder, challenge or even restrict the expansion of the Biosimilars market worldwide?
  6. What are the opportunities or future prospect for the business owners operating in the market for the forecast period, 2019 – 2026?

We are grateful to you for reading our report. If you wish to find more details of the report or want a customization, contact us. You can get a detailed information of the entire research here. If you have any special requirements, please let us know and we will offer you the report as you want.

Ask Our Expert@


Go to website